Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 33 Colorectal Neoplasms 13 Neoplasms 11 Pain, Postoperative 10 Lung Neoplasms 9 Brain Neoplasms 8 Stomach Neoplasms 7 Prostatic Neoplasms 7 Pancreatic Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Melanoma 6 Leukemia, Myeloid, Acute 5 Ovarian Neoplasms 4 Myoma 4 Lymphoma, Non-Hodgkin 4 Leiomyoma 4 Hemorrhage 4 Head and Neck Neoplasms 4 Glioblastoma 4 Colonic Neoplasms 4 Agnosia 4 Skin Neoplasms 3 Recurrence 3 Rectal Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Neurotoxicity Syndromes 3 Neoplasm Metastasis 3 Nasopharyngeal Carcinoma 3 Myelodysplastic Syndromes 3 Multiple Endocrine Neoplasia Type 1 3

Interventions

rozanolixizumab 10 zilucoplan 8 efgartigimod alfa 8 Rituximab 7 Cyclophosphamide 7 telitacicept 6 fludarabine 6 eculizumab 5 Prednisone 5 ravulizumab 4 Pyridostigmine Bromide 4 Immunoglobulins, Intravenous 4 Hizentra 4 Tacrolimus 3 Mycophenolic Acid 3 HBM9161 3 Amifampridine 3 thymoglobulin 2 inebilizumab 2 Prednisolone 2 Exercise 2 tofacitinib 1 tocilizumab 1 talquetamab 1 satralizumab 1 sargramostim 1 rhoA GTP-Binding Protein 1 remibrutinib 1 prednylidene 1 iscalimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Myasthenia Gravis × Sodium Chloride × Clear all

NCT02950155 2024-10-26

Rinomax

Karolinska Institutet

Phase 3 Completed

47 enrolled 24 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡